Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention. 1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation) Trial

JACC: Cardiovascular Interventions

Volumn 2, Issue 11, 2009, Pages 1083-1091

  Montalescot, Gilles ^a   Gallo, Richard ^b   White, Harvey D ^c   Cohen, Marc ^d   Steg, Ph Gabriel ^e   Aylward, Philip E G ^f   Bode, Christoph ^g   Chiariello, Massimo ^h   King III, Spencer B ⁱ   Harrington, Robert A ^j   Desmet, Walter J ^k   Macaya, Carlos ^l   Steinhubl, Steven R ^m,n  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b MONTREAL HEART INSTITUTE   (Canada)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^e INSERM   (France)

^f FLINDERS MEDICAL CENTRE   (Australia)

^g UNIVERSITY OF FREIBURG   (Germany)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ Saint Joseph's Heart and Vascular Institute   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l Hospital Universitario   (Spain)

^m GEISINGER MEDICAL CENTER   (United States)

ⁿ Medicines Company   (Switzerland)

more..

Author keywords

enoxaparin; percutaneous coronary intervention; STEEPLE; unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN;

AGE; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; AUSTRALIA; CANADA; ENOXAPARIN; EUROPE; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEW ZEALAND; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 70449464568     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.08.016     Document Type: Article

References (30)

1. Karsch K.R., Preisack M.B., Baildon R., et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol 28 (1996) 1437-1443
2. Dudek D., Dabrowsk M., Ochala A., et al. Multicenter, prospective, double-blind randomized comparison of enoxaparin versus unfractionated heparin for percutaneous coronary interventions (abstr). Am J Cardiol 86 8 Suppl 1 (2000) TCT-34
3. Bertel O., Ramsey D., Wettstein T., et al. The Zuerich Enoxaparin versus Unfractionated heparin Study (ZEUS) in PCI: a prospective randomized non inferiority study (abstr). Eur Heart J 27 Suppl 1 (2006) 651
4. Gibson C.M., Morrow D.A., Murphy S.A., et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol 47 (2006) 2364-2373
5. Natarajan M.K., Velianou J.L., Turpie A.G., et al. A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. Am Heart J 151 (2006) 175
6. Dumaine R., Borentain M., Bertel O., et al. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch Intern Med 167 (2007) 2423-2430
7. Montalescot G., White H.D., Gallo R., et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355 (2006) 1006-1017
8. White H.D., Kleiman N.S., Mahaffey K.W., et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 152 (2006) 1042-1050
9. Mahaffey K.W., Cohen M., Garg J., et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 294 (2005) 2594-2600
10. Zeymer U., Gitt A., Jünger C., et al. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice. Am J Cardiol 98 (2006) 19-22
11. Danchin N., Coste P., Ferrières J., et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the French registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation 118 (2008) 268-276
12. Montalescot G., de Belder M.A., Janssens L., et al. The FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial: results of the formal low molecular weight heparin substudy (abstr). Am J Cardiol 100 8 Suppl 1 (2007) S52-S53
13. Bassand J.P., Hamm C.W., Ardissino D., et al., Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28 (2007) 1598-1660
14. Manoukian S.V., Feit F., Steinhubl S.R., et al. Major bleeding is associated with increased one-year mortality and ischemic events in patients with acute coronary syndromes: results from the ACUITY trial (abstr). J Am Coll Cardiol 51 Suppl A (2008) A219
15. Kinnaird T.D., Stabile E., Mintz G.S., et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92 (2003) 930-935
16. Rao S.V., O'Grady K., Pieper M.S., et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96 (2005) 1200-1206
17. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., and Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-782
18. Yusuf S., Mehta S.R., Chrolavicius S., et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295 (2006) 1519-1530
19. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
20. Brasselet C., Tassan S., Nazeyrollas P., Hamon M., and Metz D. Randomised comparison of femoral versus radial approach for percutaneous coronary intervention using abciximab in acute myocardial infarction: results of the FARMI trial. Heart 93 (2007) 1556-1561
21. Cantor W.J., Mahaffey K.W., Huang Z., et al. Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. Catheter Cardiovasc Interv 69 (2007) 73-83
22. Jaffe R., Hong T., Sharieff W., et al. Comparison of radial versus femoral approach for percutaneous coronary interventions in octogenarians. Catheter Cardiovasc Interv 69 (2007) 815-820
23. Nageh T., Sherwood R.A., Harris B.M., Byrne J.A., and Thomas M.R. Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention. Int J Cardiol 92 (2003) 285-293
24. Kini A.S., Lee P., Marmur J.D., et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol 93 (2004) 18-23
25. Varani E., Balducelli M., Vecchi G., Gatti C., Lucchi G.R., and Maresta A. Occurrence of non-Q wave myocardial infarction following percutaneous coronary intervention in the stent era: systematic monitoring of the three markers of myocardial necrosis. J Interv Cardiol 18 (2005) 243-248
26. Thygesen K., Alpert J.S., White H.D., and Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol 50 (2007) 2173-2195
27. Singh M., Lennon R.J., Darbar D., Gersh B.J., Holmes Jr. D.R., and Rihal C.S. Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. Mayo Clin Proc 79 (2004) 1113-1118
28. Abbott J.D., Ahmed H.N., Vlachos H.A., Selzer F., and Williams D.O. Comparison of outcome in patients with ST-elevation versus non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 100 (2007) 190-195
29. Berry C., Tardif J.C., and Bourassa M.G. Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization. J Am Coll Cardiol 49 (2007) 643-656
30. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116 (2007) e148-e304